Romney Humphries Net Worth

The estimated Net Worth of Romney Humphries is at least $4.83 Tysiąc dollars as of 16 June 2020. Romney Humphries owns over 9,000 units of Accelerate Diagnostics Inc stock worth over $4,830 and over the last 5 years Romney sold AXDX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Romney Humphries AXDX stock SEC Form 4 insiders trading

Romney has made over 1 trades of the Accelerate Diagnostics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Romney exercised 9,000 units of AXDX stock worth $53,370 on 16 June 2020.

The largest trade Romney's ever made was exercising 9,000 units of Accelerate Diagnostics Inc stock on 16 June 2020 worth over $53,370. On average, Romney trades about 4,500 units every 0 days since 2020. As of 16 June 2020 Romney still owns at least 3,000 units of Accelerate Diagnostics Inc stock.

You can see the complete history of Romney Humphries stock trades at the bottom of the page.

What's Romney Humphries's mailing address?

Romney's mailing address filed with the SEC is C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON, AZ, 85714.

Insiders trading at Accelerate Diagnostics Inc

Over the last 12 years, insiders at Accelerate Diagnostics Inc have traded over $26,833,308 worth of Accelerate Diagnostics Inc stock and bought 16,366,880 units worth $209,384,489 . The most active insiders traders include Jack W Schuler, Larry N Feinberg oraz Matthew Strobeck. On average, Accelerate Diagnostics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $132,645. The most recent stock trade was executed by Hany Massarany on 28 June 2024, trading 4,737 units of AXDX stock currently worth $7,627.

What does Accelerate Diagnostics Inc do?

accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.

Complete history of Romney Humphries stock trades at Accelerate Diagnostics Inc

Accelerate Diagnostics Inc executives and stock owners

Accelerate Diagnostics Inc executives and other stock owners filed with the SEC include:

• John Phillips,
  Chief Executive Officer, Chief Operating Officer, Director
• Steve Reichling,
  Chief Financial Officer
• Jack Phillips,
  CEO, Pres & Director
• Ron Price,
  Senior Vice President, Head of Commercial Operations, Americas
• Roland Diggelmann,
  Independent Director
• Louise Francesconi,
  Independent Director
• Steve Reichling,
  CFO & Chief Accounting Officer
• Ron Price,
  Chief Commercial Officer of Americas
• Charles Watts,
  Independent Director
• Frank ten Brink,
  Independent Director
• Matthew Strobeck,
  Independent Director
• Jack Schuler,
  Independent Director
• Mark Miller,
  Independent Director
• Thomas Brown,
  Independent Director
• John Patience,
  Independent Chairman of the Board
• Nedal Safwat,
  Chief Strategy Officer
• Dr. Lawrence Mertz,
  Sr. VP and Head of R&D
• John Meduri,
  Chief Strategy Officer
• Laura Costa,
  Sr. VP & Head of Global Customer Support
• Cherif Bousselham,
  Sr. VP & Head of Sales - EMEA
• Gretchen Strohminger,
  Sr. VP and Head of HR & Culture
• Michael Bridge,
  Sr. VP, Gen. Counsel & Sec.
• Laura Pierson,
  Investor Relations Officer
• Larry N Feinberg,
  10% owner
• Pete Bantock,
  CHIEF COMMERCIAL OFFICER
• Lawrence Mehren,
  PRESIDENT AND CEO
• Marran H. Ogilvie,
  Director
• Jennifer Regan,
  Director
• Mark S. Black,
  Director
• Ventures, Llc Abeja,
  10% owner
• Romney Humphries,
  Chief Scientific Officer
• Larry Michael Mertz,
  Chief Technology Officer
• Hany Massarany,
  Director
• Jack Phillips,
  Chief Executive Officer
• Wayne Burris,
  Director
• David Patience,
  Chief Financial Officer